MAP2K7 and melanoma: Sanlorenzo et al. directly performed a retrospective cohort study, collecting data from 44 melanoma patients treated either with BRAF inhibitors (vemurafenib or dabrafenib) or BRAF and MEK inhibitor combination regimens (vemurafenib + cobimetinib or dabrafenib + trametinib) (Sanlorenzo et al., 2014).